Abstract
Verez-Bencomo V, Fernandez-Santana V, Hardy E, et al. Science . 2004;305:522–525 To demonstrate the safety and immunogenicity of synthetic glycoconjugate vaccine against Haemophilus influenzae type b (Hib). Adults, children, and infants in Camaguey, Cuba. The authors established a large-scale good manufacturing protocol for the production of ∼100-g batches of polyribosylribitol phosphate (PRP), the Hib capsular polysaccharide. Synthetic PRP (sPRP) conjugated to protein was shown to be capable of binding antibody from the serum of children immunized with commercial Hib conjugate vaccine. sPRP conjugated to tetanus toxoid …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
